SCHEMBL3548714

SCHEMBL3548714

[CH2]C(=O)NS(=O)(=O)c1ccccc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.51
CA2 P00918 5/20 0.51
CA9 Q16790 5/20 0.51
ALKBH2 Q6NS38 1/20 0.49
ALKBH3 Q96Q83 1/20 0.49
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
FBP1 P09467 1/20 0.48
KAT6A Q92794 1/20 0.48
CA12 O43570 3/20 0.47
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.44
ITGAV P06756 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206422 0.85 SLC1A3 (0.55) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL3548718 0.83 CA1 (0.52) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL11337626 0.81 CA1 (0.51) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL11337623 0.81 CA1 (0.51) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL6465947 0.81 CA1 (0.55) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL6723764 0.81 CA1 (0.51) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL29489589 0.81 CA1 (0.55) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL960240 0.81 CA1 (0.48) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL961954 0.81 CA1 (0.48) CA1CA2CA9ALKBH2ALKBH3
SCHEMBL13329854 0.80 CA1 (0.50) CA1CA2CA9ALKBH2ALKBH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696198-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
EP-1613590-A2 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2006-01-11 EP disclosed
US-20050026913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2005-02-03 US disclosed
WO-2004094375-A2 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026913-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE12, PDE3B CA1 3265/4885CA2 1082/4885CA9 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.